½ÃÀ庸°í¼­
»óǰÄÚµå
1776213

¼¼°èÀÇ Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå : ÀλçÀÌÆ®, °æÀï ±¸µµ, ½ÃÀå ¿¹Ãø(2032³â)

Intrauterine Pressure Catheter - Market Insights, Competitive Landscape, and Market Forecast - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DelveInsight | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå ±Ô¸ð´Â 2025-2032³âÀÇ ¿¹Ãø ±â°£ Áß CAGR 6.53%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¶»ê ¹× ÅÂ¾Æ °íÅë°ú °°Àº »óŸ¦ Æ÷ÇÔÇÑ º¹ÀâÇÑ ÀÓ½ÅÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó »ê¸ð¿Í žÆÀÇ ÃÖÀûÀÇ °á°ú¸¦ º¸ÀåÇϱâ À§ÇÑ Á¤¹ÐÇÑ ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ °³¹ßµµ»ó±¹ÀÇ Ãâ»êÀ² Áõ°¡·Î ÀÎÇØ Àڱó»¾Ð Ä«Å×Å͸¦ Æ÷ÇÔÇÑ Ã·´Ü ÇコÄÉ¾î ±â¼úÀÇ Çʿ伺ÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÅÂ¾Æ ¸ð´ÏÅ͸µÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Àڱà ¼öÃà¿¡ ´ëÇÑ Á¤È®ÇÑ ½Ç½Ã°£ µ¥ÀÌÅÍ¿¡ ´ëÇÑ Çʿ伺ÀÌ °­Á¶µÇ¾î ½ÃÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ Á¦Ç° °³¹ß Ȱµ¿ÀÌ ±ÞÁõÇϸ鼭 Ä«Å×ÅÍ ±â¼úÀÇ Çõ½ÅÀû ¹ßÀüÀ¸·Î À̾îÁ® ±â´É¼º°ú ¸Å·Âµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀ» Á¾ÇÕÇϸé 2025-2032³âÀÇ ¿¹Ãø ±â°£ Áß Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå ¿ªÇÐ:

¼¼°èº¸°Ç±â±¸(WHO)°¡ Á¦°øÇÑ ÃÖ±Ù µ¥ÀÌÅÍ¿Í Åë°è(2023³â)¿¡ µû¸£¸é Àü ¼¼°è¿¡¼­ ¾à 1,340¸¸ ¸íÀÇ ¾Æ±â°¡ Á¶»êÀ¸·Î ž°í ÀÖ½À´Ï´Ù. Á¶»êÀº Àڱà ¼öÃàÀÌ ºÒ±ÔÄ¢Çϰųª ºÒÃæºÐÇÑ °æ¿ì°¡ ¸¹¾Æ »ê¸ð¿Í ¾Æ±â ¸ðµÎ¿¡°Ô ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °æ¿ì, Àڱà Ȱµ¿ÀÇ Á¤È®ÇÑ ¸ð´ÏÅ͸µÀº ºÐ¸¸ ÁøÇàÀ» Æò°¡Çϰí ÀûÀýÇÑ ÀÓ»óÀû °³ÀÔÀ» °áÁ¤ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. IUPC´Â Á¤È®ÇÑ Àڱà ³»¾ÐÀ» ½Ç½Ã°£À¸·Î ÃøÁ¤ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÇ·áÁøÀº Àڱà ¼öÃàÀÇ °­µµ¿Í ºóµµ¸¦ ÁÖÀÇ ±í°Ô ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ¿ÜºÎÀûÀÎ ¹æ¹ýÀ¸·Î´Â È¿°ú°¡ ³·Àº Á¶»ê¿¡¼­ ƯÈ÷ Áß¿äÇϸç, ±× °á°ú Àü ¼¼°è IUPC ½ÃÀå Àüü°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ Àӽżº ´ç´¢º´Àº °úµµÇÑ ÅÂ¾Æ ¹ßÀ°(macrosomia)À» Æ÷ÇÔÇÑ ÀӽŠ¹× ºÐ¸¸ Áß ÇÕº´ÁõÀÇ À§ÇèÀ» Áõ°¡½Ã۰í, ºÐ¸¸ Áö¿¬ ¹× Á¦¿ÕÀý°³¼ú°ú °°Àº ÁßÀçÀÇ Çʿ伺À» ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ±¹Á¦´ç´¢º´¿¬ÇÕÀÌ Á¦°øÇÑ Ãֽе¥ÀÌÅÍ(2025³â)¿¡ µû¸£¸é 2024³â Àӽżº ´ç´¢À²Àº Àü ¼¼°è¿¡¼­ ÆíÂ÷°¡ ÀÖÀ¸¸ç, ¾ÆÇÁ¸®Ä« ¾à 10.8%, À¯·´ 13.9%, È£ÁÖ 14.9%, ÇÁ¶û½º 10.7%, Àεµ 26.1%, ½ºÆäÀÎ 37.6%, ¿µ±¹ 23.1%·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. 23.1%·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. ÀÌó·³ Àڱà ¼öÃàÀÇ Á¤È®ÇÑ ¸ð´ÏÅ͸µÀº Àӽżº ´ç´¢ ¿©¼ºÀÇ ºÐ¸¸ °ü¸®¿¡ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¿Ö³ÄÇÏ¸é ºÐ¸¸ Áß ÇÕº´ÁõÀÌ ¹ß»ýÇÒ ¼ö ÀÖ°í, Àû½Ã¿¡ Á¤È®ÇÑ °³ÀÔÀÌ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù.

¶ÇÇÑ ½ÅÈï ±¹°¡ÀÇ Ãâ»êÀ² Áõ°¡¿Í ÅÂ¾Æ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Àڱà ³»¾Ð ¸ð´ÏÅÍ ½ÃÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. °³¹ßµµ»ó±¹¿¡¼­´Â Ãâ»êÀ² Áõ°¡·Î ÀÎÇØ »ê¸ð¿Í ½Å»ý¾ÆÀÇ °Ç°­°ü¸®-ÀÎÇÁ¶ó °³¼±¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ÀÌµé ±¹°¡¿¡¼­´Â Áõ°¡ÇÏ´Â Àӽмö¸¦ °ü¸®Çϱâ À§ÇØ ´õ ³ªÀº ÀÇ·á½Ã¼³°ú ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖÀ¸¸ç, Àڱà ³»¾Ð ¸ð´ÏÅÍ¿Í °°Àº ÷´Ü ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ Àڱà ±â´É ºÎÀüÀ̳ª ÅÂ¾Æ °íÅë°ú °°Àº ÇÕº´ÁõÀº Á¶±â¿¡ ¹ß°ßµÇÁö ¾ÊÀ¸¸é ½É°¢ÇÑ °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¹Ç·Î ƯÈ÷ ºÐ¸¸ Áß ÅÂ¾Æ ¸ð´ÏÅ͸µÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. Àڱà ³»¾Ð ¸ð´ÏÅÍ´Â Àڱà ¼öÃà¿¡ ´ëÇÑ ½Ç½Ã°£ Á¤È®ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇϹǷΠÀÇ·áÁøÀÌ ÇÕº´Áõ ¹ß»ý½Ã ½Å¼ÓÇÏ°Ô °³ÀÔÇÒ ¼ö ÀÖÀ¸¸ç, Àü ¼¼°è Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå Àüü¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ Á¸Àç´Â Àڱó»¾Ð Ä«Å×ÅÍÀÇ ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ÁøÀÔ±â¾÷ÀÎ CooperSurgicalÀº »êºÎÀΰú Àåºñ ½ÃÀåÀÇ Áö¹èÀûÀÎ ÁøÀÔ±â¾÷ÀÔ´Ï´Ù. ÀÌ È¸»çÀÇ IUPCÀÎ Intran Plus(TM)¿Í Intran Plus(TM) Disposable IUPC´Â ºÐ¸¸½Ã Àڱà ³»¾ÐÀ» Á¤È®ÇÏ°Ô ÃøÁ¤ÇÏ´Â °ÍÀ¸·Î À¯¸íÇÕ´Ï´Ù. ±¤¹üÀ§ÇÑ º´¿ø ³×Æ®¿öÅ©, Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å, »êºÎÀΰú ÀÇ·á¿¡ ´ëÇÑ ÁýÁßÀº »êºÎÀΰú º´µ¿¿¡¼­ÀÇ Á¦Ç° äÅÃÀ» °­·ÂÇÏ°Ô ÃßÁøÇÏ¿© ¼¼°è ½ÃÀå ħÅõ¸¦ Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

µû¶ó¼­ À§ÀÇ ¿äÀεéÀº 2025-2032³âÀÇ ¿¹Ãø ±â°£ Áß Àüü Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

±×·¯³ª °¨¿°À̳ª ºÒÆíÇÔÀÇ À§Çè, Àڱø· ÆÄ¿­, ÅÂ¹Ý ÀÌ»ó, ƯÁ¤ ÁúȯÀ» °¡Áø ¿©¼ºÀº Àڱó»¾ÐÄ«Å×ÅÍ »ðÀÔÀ» ÇÒ ¼ö ¾ø´Â µî ÀÌ¿ë »ç·Ê°¡ Á¦ÇÑÀûÀ̱⠶§¹®¿¡ Àڱó»¾ÐÄ«Å×ÅÍ ½ÃÀå ¼ºÀåÀÇ Á¦ÇÑ ¿äÀÎÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

Àڱó»¾Ð Ä«Å×ÅÍ ½ÃÀå ºÎ¹® ºÐ¼® :

Àڱó»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ Á¦Ç° ºÎ¹®¿¡¼­´Â 2024³â Æ®·£½ºµà¼­ ÆÁ Ä«Å×ÅÍ Ä«Å×°í¸®°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Æ®·£½ºµà¼­ ÆÁ Ä«Å×Åʹ ÷´Ü ±â¼ú°ú Àڱà ¼öÃà ¸ð´ÏÅ͸µÀÇ Á¤È®µµ Çâ»óÀ¸·Î Àüü Àڱó»¾Ð Ä«Å×ÅÍ(IUPC) ½ÃÀåÀ» ÃËÁøÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. Æ®·£½ºµà¼­ ÆÁ Ä«Å×ÅÍ´Â Ä«Å×ÅÍ ³¡¿¡ ¼¾¼­°¡ ³»ÀåµÇ¾î ÀÖÀ¸¸ç, Àڱà ³»¾ÐÀ» Á÷Á¢ ÃøÁ¤ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ¾×ü¸¦ »ç¿ëÇÏ´Â ½Ã½ºÅÛÀÇ Á¤È®¼ºÀ» ¹æÇØÇÏ´Â ±âÆ÷ ¹× ±âŸ ¹®Á¦ÀÇ À§ÇèÀ» Á¦°ÅÇÏ¿© Àڱà Ȱµ¿¿¡ ´ëÇÑ º¸´Ù ½Å·ÚÇÒ ¼ö ÀÖ´Â µ¥ÀÌÅ͸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. Æ®·£½ºµà¼­ ÆÁ Ä«Å×ÅͰ¡ Á¦°øÇÏ´Â ½Ç½Ã°£ÀÇ Á¤È®ÇÑ ÃøÁ¤°ªÀº ÀÇ·áÁøÀÌ ºÐ¸¸ ÁøÇàÀ» ¸ð´ÏÅ͸µÇϰí ÇÕº´ÁõÀ» Á¶±â¿¡ ¹ß°ßÇϸç Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÓ»óÀû ÆÇ´ÜÀ» ³»¸± ¼ö ÀÖ´Â ´É·ÂÀ» Çâ»ó½ÃÄÑ ÁÝ´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ Ä«Å×ÅÍÀÇ »ç¿ë ÆíÀǼº°ú ¼º´É Çâ»óÀ¸·Î ÀÎÇØ ÀÇ·áÁø¿¡°Ô ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡°¥ ¼ö ÀÖÀ¸¸ç, º´¿ø°ú ºÐ¸¸ ¼¾ÅÍ¿¡¼­ÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ÀÇ·á ±â°üÀÌ È¯ÀÚÀÇ ¾ÈÀü°ú °á°úÀÇ Á¤È®¼ºÀ» ÃÖ¿ì¼± °úÁ¦·Î »ï°í ÀÖ´Â °¡¿îµ¥, Æ®·£½ºµà¼­Ä¨ IUPC¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 Àüü IUPC ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. Á¤È®ÇÑ µ¥ÀÌÅͰ¡ Áß¿äÇÑ °íÀ§Çè Àӽſ¡¼­ ¿ì¼öÇÑ ¸ð´ÏÅ͸µ ±â´ÉÀ» Á¦°øÇÏ´Â ÀÌ È¸»çÀÇ ´É·ÂÀº ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ¿ªÇÒÀ» ´õ¿í È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Clinical Innovations(Laborie ºê·£µå)ÀÇ Koala(R) Àڱó»¾Ð Ä«Å×ÅÍ´Â ÃøÁ¤ ¿À·ùÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí Á¤È®ÇÑ Àڱó»¾Ð ÃøÁ¤°ªÀ» Á¦°øÇÏ´Â Æ®·£½ºµà¼­ ÆÁ Ä«Å×ÅÍÀÇ ´ëÇ¥ÀûÀÎ ¿¹ÀÔ´Ï´Ù. ¸¶Âù°¡Áö·Î ¸ÞµåÆ®·Î´ÐÀÇ INTRAN(TM) Plus Disposable IUPC´Â »ðÀÔÀ» °£¼ÒÈ­ÇÏ°í ³»ºÎ Æ®·£½ºµà¼­ ĨÀ» ÅëÇØ º¸´Ù ½Å·ÚÇÒ ¼ö ÀÖ´Â ÃøÁ¤°ªÀ» Á¦°øÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÓ»óÀÇÀÇ ¾÷¹« ºÎ´ãÀ» ÁÙÀ̰í, ȯÀÚÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½Ã۸ç, ¼ö¼ú °ü·Ã ÇÕº´ÁõÀ» ÁÙÀÌ´Â º´¿øÀÇ ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â °ÍÀÔ´Ï´Ù.

µû¶ó¼­ À§ÀÇ ¸ðµç ¿äÀÎÀº ¿¹Ãø ±â°£ Áß ¼¼°è Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ Àü¹ÝÀûÀÎ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ºÎ¹®¿¡ »ó´çÇÑ ¸ÅÃâÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ðµç Áö¿ª Áß ºÏ¹Ì´Â 2024³â ¼¼°è Àڱó»¾Ð Ä«Å×ÅÍ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â Á¶»êÀ² Áõ°¡, ÀӽŠÁß ÇÕº´Áõ Áõ°¡, ºÐ¸¸½Ã »ê¸ð¿Í ¾ÆÀÌÀÇ ¾ÈÀü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½ÅÁ¦Ç° ¹× ÷´Ü Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÃÖ¼Ò Ä§½À ¼ö¼úÀÇ Ã¤Åà Áõ°¡, ÀÌ Áö¿ª¿¡¼­ Àü·«Àû Ȱµ¿À» ¼öÇàÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç µîÀÌ ÀÖ½À´Ï´Ù.

¹Ì±¹ Áúº´¿¹¹æÅëÁ¦¼¾ÅÍ(CDC)°¡ Á¦°øÇÑ µ¥ÀÌÅÍ(2024³â)¿¡ µû¸£¸é 2022³â ¹Ì±¹ÀÇ Ãâ»êÀ²Àº Àα¸ 1,000¸í´ç 11¸í, 15-44¼¼ ¿©¼º 1,000¸í´ç 56.3¸íÀ̾ú½À´Ï´Ù. Ãâ»êÀ²ÀÌ ³ô´Ù´Â °ÍÀº ºÐ¸¸Áö¿¬, Àڱñâ´ÉºÎÀü, žƹßÀ°ºÎÀü µîÀÇ ÇÕº´ÁõÀ» ÇÇÇϱâ À§ÇØ ¼¼½ÉÇÑ °üÂûÀÌ ÇÊ¿äÇÑ ÀÓ½ÅÀÌ ¸¹´Ù´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ°¡ »ê¸ð¿Í ½Å»ý¾ÆÀÇ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ³ë·ÂÇÔ¿¡ µû¶ó ±×µéÀº Á¡Á¡ ´õ ¸¹Àº IUPC¸¦ äÅÃÇÏ¿© Ãâ»ê Áß ´õ ³ªÀº ÅëÁ¦¿Í °ü¸®¸¦ º¸ÀåÇϱâ À§ÇØ IUPC¸¦ äÅÃÇϰí ÀÖÀ¸¸ç, ÀÌ·Î ÀÎÇØ Àڱó» ¾Ð·Â Ä«Å×ÅÍ ½ÃÀåÀº Áö¿ª Àüü¿¡ Ȱ·ÂÀ» ºÒ¾î³ÖÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¶ÇÇÑ Áúº´°ü¸®º»ºÎ(Centre for Disease Control and Prevention)°¡ Á¦°øÇÑ ÃÖ±Ù µ¥ÀÌÅÍ(2023³â)¿¡ µû¸£¸é ÀӽŠÁß ´ç´¢º´(Àӽżº ´ç´¢) Áø´ÜÀ» ¹Þ°í Ãâ»êÇÏ´Â »ê¸ðÀÇ ºñÀ²Àº 2021³â 6.0%¿¡¼­ 8.3%·Î Áõ°¡Çß½À´Ï´Ù. Áõ°¡Çß½À´Ï´Ù. IUPC´Â Àڱà ³»¾ÐÀÇ Á¤È®ÇÑ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ Á¦°øÇϹǷΠÀÇ·áÁøÀº ÀÌ»ó ¡Èĸ¦ °¨ÁöÇÏ°í ½Å¼ÓÇÏ°Ô ´ëÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ Àӽżº ´ç´¢ »ç·Ê°¡ Áõ°¡Çϰí, ƯÈ÷ ÀÓ»êºÎÀÇ ¿¬·É°ú ºñ¸¸ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó IUPC¿Í °°Àº ÷´Ü ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¿© ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¶ÇÇÑ ÀÌ Áö¿ªÀÇ ¿©¼º Àα¸ Áõ°¡´Â Àڱó»¾Ð Ä«Å×ÅÍ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î ¼¼°èº¸°Ç±â±¸(WHO)°¡ ¹ßÇ¥ÇÑ Ãֽе¥ÀÌÅÍ(2022³â)¿¡ µû¸£¸é ¹Ì±¹³» ÀÓ»êºÎ »ç¸ÁÀÇ ¾à Àý¹ÝÀº ÀÎ½Ä °³¼±°ú ÀÓ»êºÎ°¡ ¾çÁúÀÇ ÀÇ·á ¼­ºñ½º¸¦ ¹ÞÀ» ¼ö ÀÖ´Ù¸é ¿¹¹æÀÌ °¡´ÉÇÏ´Ù°í ÇÕ´Ï´Ù. ¶ÇÇÑ ÃÖ´ë 5¸¸ ¸íÀÇ ¿©¼ºÀÌ ÀӽŠÁß, Ãâ»ê ½Ã, »êÈÄ¿¡ ½É°¢ÇÑ ÇÕº´ÁõÀ» °æÇèÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Åë°è´Â »ê¸ð ¸ð´ÏÅ͸µÀÇ °³¼±°ú Áú ³ôÀº »ê°ú ÀÇ·áÀÇ ½Ã±ÞÇÑ Çʿ伺À» °­Á¶Çϸç, Àڱó»¾ÐÄ«Å×ÅÍ(IUPC) ¼ö¿ä Áõ°¡¸¦ Á÷Á¢ÀûÀ¸·Î Áö¿øÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹³» »ê¸ð »ç¸ÁÀÇ Àý¹ÝÀÌ ¿¹¹æ °¡´ÉÇÏ´Ù´Â »ç½ÇÀº IUPC°¡ Àڱà ¼öÃà¿¡ ´ëÇÑ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àڱà ÆÄ¿­À̳ª ºÒÃæºÐÇÑ ºÐ¸¸ ÁøÇà°ú °°Àº ÇÕº´ÁõÀ» ¿¹¹æÇÔÀ¸·Î½á Å« ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ¿µ¿ª¿¡¼­ Àû½Ã¿¡ Á¤È®ÇÑ ºÐ¸¸ ¸ð´ÏÅ͸µÀÇ Áß¿äÇÑ ¿ªÇÒÀ» °­Á¶ÇÕ´Ï´Ù. Áß¿äÇÑ ¿ªÇÒÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

µû¶ó¼­ À§ÀÇ ¸ðµç ¿äÀÎÀÇ »óÈ£ ÀÛ¿ëÀ¸·Î ÀÎÇØ ºÏ¹ÌÀÇ Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀº ¿¹Ãø ±â°£ Áß È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷:

Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡´Â Cardinal Health, Koninklijke Philips N.V., Utah Medical Products, Inc., CooperSurgical Inc., Thomas Medical, VYAIRE, Laborie, LABOTECT GMBH, Kentec Medical, Inc., General Electric Company, Famasys Inc., MicroPort Scientific Corporation µîÀÌ ÀÖ½À´Ï´Ù.

Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ ÃÖ±Ù °³¹ß Ȱµ¿:

  • 2022³â 12¿ù, ¿©¼º »ý½Ä °Ç°­¿¡ ÃÊÁ¡À» ¸ÂÃá ¹ÙÀÌ¿À¸ÞµðÄà ±â¾÷ Famasys Inc.´Â ¼±ÅÃÀû ³­°ü Æò°¡¸¦ À§ÇÑ ÃÖÃÊÀÇ FDA ½ÂÀÎ Àڱó» Ä«Å×ÅÍÀÎ FemCath(TM) Á¦Ç°ÀÌ ½ÃÆÇµÇ¾ú´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.
  • 2021³â 4¿ù, MicroPort Scientific CorporationÀÇ ÀÚȸ»çÀÎ Shanghai Horizon Medical Technology Co.Ltd.ÀÇ Á¦Ç°ÀÎ Àڱó» Àΰø¼öÁ¤ Ä«Å×ÅÍ Orkid(R)°¡ »óÇÏÀ̽à ¾àǰ°¨µ¶°ü¸®±¹À¸·ÎºÎÅÍ µî·ÏÁõÀ» ÃëµæÇÏ¿´´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. µî·ÏÁõÀ» ÃëµæÇÏ¿´´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

Àڱó» ÇÇÀÓ Ä«Å×ÅÍ ½ÃÀå Á¶»ç º¸°í¼­ÀÇ ÁÖ¿ä ¿äÁ¡

  • Àڱó»¾ÐÄ«Å×ÅÍ ½ÃÀå ±Ô¸ð ºÐ¼®(2024³â), 8³â°£(2025-2032³â) ½ÃÀå ¿¹Ãø
  • ÃÖ±Ù 3³â°£ ÁÖ¿ä Á¦Ç°/±â¼ú °³¹ß, ÇÕº´, Àμö, Á¦ÈÞ, ÇÕÀÛÅõÀÚ, ÇÕº´, ÀμöÇÕº´, Á¦ÈÞ, ÇÕÀÛÅõÀÚ
  • Àڱó»¾Ð Ä«Å×ÅÍ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷
  • Àڱó»¾ÐÄ«Å×ÅÍ ½ÃÀåÀÇ °æÀï¾÷üµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ´Ù¾çÇÑ ±âȸµé
  • 2024³â »óÀ§±Ç ºÎ¹®°ú 2032³â ÀÌµé ºÎ¹®ÀÇ ¼º°ú
  • ÇöÀç Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå ½Ã³ª¸®¿À¿¡¼­ »óÀ§ ½ÇÀûÀ» ¿Ã¸° Áö¿ª ¹× ±¹°¡´Â ´ÙÀ½°ú °°½À´Ï´Ù.
  • ÇâÈÄ ±â¾÷ÀÌ Àڱó»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ ¼ºÀå ±âȸ¿¡ ÁýÁßÇØ¾ß ÇÒ Áö¿ª ¹× ±¹°¡

Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå ÀÚÁÖ ¹¯´Â Áú¹®

1. Àڱà ³»¾Ð Ä«Å×ÅÍ

  • Àڱó»¾ÐÄ«Å×ÅÍ(IUPC)´Â ºÐ¸¸ Áß Àڱà ¼öÃàÀ» ¸ð´ÏÅ͸µÇϱâ À§ÇØ ÀÓ»êºÎÀÇ Àڱà ³»¿¡ »ðÀÔÇÏ´Â ÀåÄ¡ÀÔ´Ï´Ù. Ä«Å×ÅÍ´Â ºÐ¸¸ Áß ¾ç¸·°­³» ¾Ð·ÂÀ» ÃøÁ¤ÇÏ¿© Àǻ簡 ÁøÅëÀÇ °­µµ, ºóµµ, Áö¼Ó ½Ã°£À» Æò°¡ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

2. Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå

  • Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀº 2025-2032³âÀÇ ¿¹Ãø ±â°£ Áß ¿¬Æò±Õ 6.53%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

3. Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ

  • Á¶»ê, ÅÂ¾Æ °íÅë µî º¹ÀâÇÑ ÀÓ½ÅÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó »ê¸ð¿Í žÆÀÇ °á°ú¸¦ ÃÖÀûÈ­Çϱâ À§ÇÑ Á¤¹ÐÇÑ ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡, °³¹ßµµ»ó±¹ÀÇ Ãâ»êÀ² Áõ°¡´Â À̵é Áö¿ªÀÌ ÀÇ·á ÀÎÇÁ¶ó¸¦ °­È­ÇÔ¿¡ µû¶ó IUPC¸¦ Æ÷ÇÔÇÑ Ã·´Ü ÀÇ·á ±â¼úÀÇ Çʿ伺À» È®´ë½Ã۰í ÀÖ½À´Ï´Ù. ÅÂ¾Æ ¸ð´ÏÅ͸µÀÇ Á߿伺¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Àڱà ¼öÃà¿¡ ´ëÇÑ Á¤È®ÇÑ ½Ç½Ã°£ µ¥ÀÌÅÍÀÇ Çʿ伺ÀÌ °­Á¶µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷º° Á¦Ç° °³¹ß Ȱµ¿ÀÌ ±ÞÁõÇϸ鼭 Ä«Å×ÅÍ ±â¼úÀÇ Çõ½ÅÀû ¹ßÀüÀ¸·Î À̾îÁ® ±â´É¼º°ú ¸Å·Âµµ¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀ» Á¾ÇÕÇϸé 2025-2032³âÀÇ ¿¹Ãø ±â°£ Áß IUPCs ½ÃÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

4. Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇÏ´Â ÁÖ¿ä ±â¾÷

  • Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå¿¡¼­ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡´Â Cardinal Health, Koninklijke Philips N.V., Utah Medical Products, Inc., CooperSurgical Inc., Thomas Medical, VYAIRE, Laborie, LABOTECT GMBH, Kentec Medical, Inc., General Electric Company, Femapys Inc., MicroPort Scientific Corporation µîÀÌ ÀÖ½À´Ï´Ù.

5. Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå¿¡¼­ °¡Àå ³ôÀº Á¡À¯À²À» °¡Áø Áö¿ª

  • ¸ðµç Áö¿ª Áß ºÏ¹Ì´Â 2024³â ¼¼°è Àڱó»¾Ð Ä«Å×ÅÍ ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î´Â Á¶»êÀ² Áõ°¡, ÀӽŠÁß ÇÕº´Áõ Áõ°¡, ºÐ¸¸½Ã »ê¸ð¿Í ¾ÆÀÌÀÇ ¾ÈÀü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ½ÅÁ¦Ç°-÷´Ü Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÃÖ¼Ò Ä§½ÀÀû ½Ã¼úÀÇ Ã¤Åà Áõ°¡, ÀÌ Áö¿ª¿¡¼­ Àü·«Àû Ȱµ¿À» ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ Á¸Àç µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå º¸°í¼­ ¼­·Ð

Á¦2Àå Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå °³¿ä

Á¦3Àå °æÀï ±¸µµ

Á¦4Àå ±ÔÁ¦ ºÐ¼®

  • ¹Ì±¹
  • À¯·´
  • ÀϺ»
  • Áß±¹

Á¦5Àå Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ ÁÖ¿ä ¿äÀÎ ºÐ¼®

  • Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ÇÕº´Áõ ÀÓ½ÅÀÇ Áõ°¡
    • °³¹ßµµ»ó Áö¿ª¿¡¼­ Ãâ»ý·üÀÇ »ó½Â
    • ÅÂ¾Æ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó
    • Àü ¼¼°èÀÇ ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷º° Á¦Ç° °³¹ß Ȱµ¿ÀÇ Áõ°¡
  • Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
    • °¨¿° ¹× ºÒÄè°¨ÀÇ ¸®½ºÅ©
    • RM(ruptured membranes), ÅÂ¹Ý ÀÌ»ó ¶Ç´Â ƯÁ¤ º´»óÀ» °¡Áø ¿©¼º µî ƯÁ¤ ÄÉÀ̽º¿¡¼­´Â »ç¿ëÀÌ Á¦ÇѵȴÙ.
  • Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ ±âȸ
    • Ä«Å×ÅÍ ±â¼úÀÇ °³·®¿¡ ÀÇÇØ Àڱà ³»¾Ð Ä«Å×ÅÍ´Â º¸´Ù ¾ÈÀüÇØÁö¸ç, º¸´Ù ÀÏ»óÀûÀÎ Áõ·Ê¿¡ Àû¿ëÇÒ ¼ö ÀÖ°Ô µÇ°í ÀÖ´Ù.

Á¦6Àå Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå : Porter's Five Forces ºÐ¼®

Á¦7Àå Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀå Æò°¡

  • Á¦Ç°º°
    • ¾×ü ÃæÀü Ä«Å×ÅÍ
    • Æ®·£½ºµà¼­ Ĩ Ä«Å×ÅÍ
  • ÃÖÁ¾»ç¿ëÀÚº°
    • º´¿ø
    • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ(ASC)
    • Àü¹® Ŭ¸®´Ð
  • Áö¿ªº°
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±âŸ Áö¿ª

Á¦8Àå Àڱà ³»¾Ð Ä«Å×ÅÍ ½ÃÀåÀÇ ±â¾÷°ú Á¦Ç° °³¿ä

  • Cardinal Health
  • Koninklijke Philips N.V.
  • Utah Medical Products, Inc.
  • CooperSurgical Inc.
  • Thomas Medical
  • VYAIRE
  • Laborie
  • LABOTECT GMBH
  • Kentec Medical, Inc.
  • General Electric Company
  • Femasys Inc.
  • MicroPort Scientific Corporation

Á¦9Àå KOLÀÇ °ßÇØ

Á¦10Àå ÇÁ·ÎÁ§Æ® ¾îÇÁ·ÎÄ¡

Á¦11Àå DelveInsight ¼Ò°³

Á¦12Àå ¸éÃ¥»çÇ×°ú ¹®ÀÇ

KSA 25.07.31

Intrauterine Pressure Catheters (IUPCs) Market by Product (Fluid-Filled Catheters and Transducer Tip Catheters), End-User (Hospitals, Ambulatory Surgical Centers (ASCS), and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising incidence of complicated pregnancies, rising birth rates in developing regions, growing awareness of fetal monitoring, and increase in product development activities by key market players across the globe.

The intrauterine pressure catheters market is estimated to grow at a CAGR of 6.53% during the forecast period from 2025 to 2032. The rising incidence of complicated pregnancies, including conditions like preterm labor and fetal distress, drives the demand for precise monitoring solutions to ensure optimal maternal and fetal outcomes. Concurrently, increasing birth rates in developing regions are expanding the need for advanced healthcare technologies, including intrauterine pressure catheters. Additionally, the growing awareness of the importance of fetal monitoring underscores the necessity for accurate and real-time data on uterine contractions, further propelling the market. Furthermore, the surge in product development activities by key market players is leading to innovative advancements in catheter technology, which enhances their functionality and appeal. Collectively, these factors are expected to boost the market for intrauterine pressure catheters during the forecast period from 2025 to 2032.

Intrauterine Pressure Catheters Market Dynamics:

According to the recent data and stats provided by the World Health Organization (2023), an estimated 13.4 million babies were born preterm across the globe. Preterm labor often involves irregular or insufficient uterine contractions, which can lead to complications for both the mother and the baby. In such cases, precise monitoring of uterine activity is crucial to assess labor progression and determine the appropriate clinical interventions. IUPCs provide accurate, real-time measurement of intrauterine pressure, allowing healthcare providers to closely monitor the strength and frequency of contractions, which is particularly important in preterm labor where external methods may be less effective thereby escalating the overall market of IUPCs across the globe.

Furthermore, gestational diabetes increases the risk of complications during pregnancy and labor, including excessive fetal growth (macrosomia), which can lead to prolonged labor or the need for interventions such as C-sections. For instance, as per the latest data provided by the International Diabetes Federation (2025), in 2024 gestational diabetes mellitus rates varied globally, with approximately 10.8% reported in Africa, 13.9% in Europe, 14.9% in Australia, 10.7% in France, 26.1% in India, 37.6% in Spain, and 23.1% in the United Kingdom. Thus, accurate monitoring of uterine contractions becomes crucial in managing labor for women with gestational diabetes, as complications can arise during delivery that require timely and precise interventions.

Furthermore, the rising birth rates in developing regions and growing awareness of fetal monitoring are other key factors collectively driving the market for intrauterine pressure monitors. In developing regions, increasing birth rates are putting more focus on improving maternal and neonatal healthcare infrastructure. As these countries invest in better medical facilities and technologies to manage the growing number of pregnancies, the demand for advanced monitoring solutions, like intrauterine pressure monitors, is on the rise. At the same time, there is a heightened awareness of the importance of fetal monitoring, especially during labor, as complications like uterine dysfunction and fetal distress can lead to severe outcomes if not detected early. Intrauterine pressure monitors provide real-time, accurate data on uterine contractions, enabling healthcare providers to intervene swiftly when complications arise thereby boosting the overall market of intrauterine pressure catheters across the globe.

Additionally, the presence of key market players is further contributing to the growth of intrauterine pressure catheters. Major player CooperSurgical which is a dominant player in the obstetrics and gynecology device market. Their IUPCs such as Intran Plus(TM), and Intran Plus(TM) Disposable IUPC are known for accuracy in intrauterine pressure measurement during labor. The company's broad hospital network, continuous innovation, and OB-GYN focus drive strong product adoption in maternity wards, significantly boosting market penetration worldwide.

Thus, the factors mentioned above are expected to boost the overall market of intrauterine pressure catheters during the forecast period from 2025 to 2032.

However, the risk of infection and discomfort and limited use in certain cases such as women with ruptured membranes, placental abnormalities, or certain medical conditions may not be candidates for IUPC insertion thus, these may be the limiting factors for the intrauterine pressure catheters market growth.

Intrauterine Pressure Catheters Market Segment Analysis:

Intrauterine Pressure Catheters (IUPCs) Market by Product (Fluid-Filled Catheters and Transducer Tip Catheters), End-User (Hospitals, Ambulatory Surgical Centers (ASCS), and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the intrauterine pressure catheters market, the transducer tip catheters category is expected to hold the largest share in the year 2024. Transducer tip catheters are playing a significant role in boosting the overall market of intrauterine pressure catheters (IUPCs) due to their advanced technology and enhanced accuracy in monitoring uterine contractions. Transducer tip catheters feature a built-in sensor at the catheter's tip, which allows for direct measurement of intrauterine pressure. This technology eliminates the risk of air bubbles and other issues that can interfere with the accuracy of fluid-based systems, providing more reliable data on uterine activity. The real-time, precise readings offered by transducer tip catheters improve the ability of healthcare providers to monitor labor progression, detect complications early, and make informed clinical decisions. Additionally, the ease of use and improved performance of these catheters have made them more appealing to medical professionals, leading to increased adoption in hospitals and birthing centers.

As healthcare facilities continue to prioritize patient safety and outcome accuracy, the demand for transducer tip IUPCs is rising, contributing to the overall growth of the IUPC market. Their ability to offer superior monitoring capabilities in high-risk pregnancies, where accurate data is crucial, further solidifies their role in driving market expansion. For instance, Koala(R) Intrauterine Pressure Catheter by Clinical Innovations (a Laborie brand) is a prominent example of a transducer tip catheter that offers accurate uterine pressure readings with minimal risk of measurement error. Similarly, the INTRAN(TM) Plus Disposable IUPC by Medtronic is designed to simplify insertion and deliver reliable readings with an internal transducer tip. These innovations help reduce clinician workload, improve patient safety, and align with hospital goals of reducing intervention-related complications.

Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global intrauterine pressure catheters market during the forecast period.

North America is expected to dominate the overall intrauterine pressure catheters market:

Among all the regions, North America is expected to hold the largest share of the global intrauterine pressure catheters market in 2024. The key driving factors of the intrauterine pressure catheters market are the increasing prevalence of preterm birth, increasing complications in pregnancies, increasing awareness among the people about the safety of mother and child during the delivery, growing demand for new and advanced products, increased adoption of minimally invasive procedure, and the presence of key players engaged in strategic activities in the region.

According to the data provided by the Centers for Disease Control and Prevention (CDC) (2024), in 2022, the birth rate was 11 per 1000 people and the fertility rate was 56.3 births per 1000 women aged between 15-44 in the United States. Higher birth rates mean more pregnancies that may require careful monitoring to avoid complications such as prolonged labor, uterine dysfunction, or fetal distress. As healthcare providers strive to improve maternal and neonatal outcomes, they increasingly adopt IUPCs to ensure better control and management during childbirth thereby the market of intrauterine pressure catheters is expected to boost across the region.

Additionally, as per the recent data provided by the Centre for Disease Control and Prevention (2023), the percentage of mothers giving birth who received a diagnosis of diabetes during pregnancy (gestational diabetes) increased from 6.0% to 8.3% in 2021. IUPCs provide accurate, real-time data on uterine pressure, allowing healthcare providers to detect any irregularities and respond promptly. As gestational diabetes cases rise globally, especially with increasing maternal age and obesity, the demand for advanced monitoring solutions like IUPCs is expected to grow, driving market expansion.

Furthermore, the growing female population in the region will in turn propel the demand for intrauterine pressure catheters. For instance, according to the latest data presented by the World Health Organization (WHO) (2022), about half of maternal deaths in the United States were preventable, so long as there's increased awareness and pregnant women can get access to quality care. Also, Up to 50,000 women may experience severe complications during pregnancy, at delivery, or in the postpartum period. These statistics highlight the urgent need for improved maternal monitoring and quality obstetric care, directly supporting the growing demand for intrauterine pressure catheters (IUPCs). The fact that half of maternal deaths in the U.S. are preventable underscores the critical role of timely and accurate labor monitoring in an area where IUPCs can make a substantial impact by providing real-time data on uterine contractions, helping to prevent complications such as uterine rupture or inadequate labor progression.

Hence, the interplay of all the above-mentioned factors is anticipated to augment the market for intrauterine pressure catheters in the region during the forecasted period in North America.

Intrauterine Pressure Catheters Market Key Players:

Some of the key market players operating in the intrauterine pressure catheters market include Cardinal Health, Koninklijke Philips N.V., Utah Medical Products, Inc., CooperSurgical Inc., Thomas Medical, VYAIRE, Laborie, LABOTECT GMBH, Kentec Medical, Inc., General Electric Company, Femasys Inc., MicroPort Scientific Corporation, and others.

Recent Developmental Activities in the Intrauterine Pressure Catheters Market:

  • In December 2022, Femasys Inc., a biomedical company focused on women's reproductive health, announced that its product FemCath(TM), the first FDA-cleared intrauterine catheter for selective tubal evaluation, became commercially available.
  • In April 2021, MicroPort Scientific Corporation announced Orkid(R) intrauterine insemination catheter, a product by Shanghai Horizon Medical Technology Co., Ltd., a subsidiary of MicroPort Scientific Corporation, received the registration certificate from the Shanghai Municipal Drug Administration.

Key takeaways from the intrauterine pressure catheters market report study:

  • Market size analysis for current intrauterine pressure catheters size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the intrauterine pressure catheters market.
  • Various opportunities available for the other competitors in the intrauterine pressure catheters market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current intrauterine pressure catheters market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for intrauterine pressure catheter market growth in the coming future?

Target audience who can benefit from this intrauterine pressure catheters market report study:

  • Intrauterine pressure catheter product providers
  • Research organizations and consulting companies
  • Intrauterine pressure catheters-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in intrauterine pressure catheters
  • Various end-users who want to know more about the intrauterine pressure catheters market and the latest technological developments in the intrauterine pressure catheters market.

Frequently Asked Questions for the Intrauterine Pressure Catheters Market:

1. What are intrauterine pressure catheters?

  • An intrauterine pressure catheter (IUPC) is a device placed inside a pregnant woman's uterus to monitor uterine contractions during labor. The catheter measures the pressure within the amniotic space during contractions and allows physicians to evaluate the strength, frequency, and duration of contractions.

2. What is the market for intrauterine pressure catheters?

  • The intrauterine pressure catheters market is estimated to grow at a CAGR of 6.53% during the forecast period from 2025 to 2032.

3. What are the drivers for the intrauterine pressure catheter market?

  • The rising incidence of complicated pregnancies, including conditions like preterm labor and fetal distress, drives the demand for precise monitoring solutions to ensure optimal maternal and fetal outcomes. Concurrently, increasing birth rates in developing regions are expanding the need for advanced healthcare technologies, including IUPCs, as these areas enhance their medical infrastructure. Growing awareness of the importance of fetal monitoring underscores the necessity for accurate and real-time data on uterine contractions, further propelling the market. Additionally, the surge in product development activities by key market players is leading to innovative advancements in catheter technology, which enhances their functionality and appeal. Collectively, these factors are expected to boost the market for IUPCs during the forecast period from 2025 to 2032.

4. Who are the key players operating in the intrauterine pressure catheter market?

  • Some of the key market players operating in the intrauterine pressure catheters market include Cardinal Health, Koninklijke Philips N.V., Utah Medical Products, Inc., CooperSurgical Inc., Thomas Medical, VYAIRE, Laborie, LABOTECT GMBH, Kentec Medical, Inc., General Electric Company, Femasys Inc., MicroPort Scientific Corporation, and others.

5. Which region has the highest share in the intrauterine pressure catheters market?

  • Among all the regions, North America is expected to hold the largest share of the global intrauterine pressure catheters market in 2024. The key driving factors of the intrauterine pressure catheters market are the increasing prevalence of preterm birth, increasing complications in pregnancies, increasing awareness among the people about the safety of mother and child during the delivery, growing demand for new and advanced products, increased adoption of minimally invasive procedure, and the presence of key players engaged in strategic activities in the region.

Table of Contents

1. Intrauterine Pressure Catheters Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Intrauterine Pressure Catheters Market Executive Summary

  • 2.1 Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1 The United States
  • 4.2 Europe
  • 4.3 Japan
  • 4.4 China

5. Intrauterine Pressure Catheters Market Key Factors Analysis

  • 5.1. Intrauterine Pressure Catheters Market Drivers
    • 5.1.1 The rising incidence of complicated pregnancies
    • 5.1.2 Rising birth rates in developing regions
    • 5.1.3 Growing awareness of fetal monitoring
    • 5.1.4 Increase in product development activities by key market players across the globe.
  • 5.2 Intrauterine Pressure Catheters Market Restraints and Challenges
    • 5.2.1 Risk of infection and discomfort
    • 5.2.2 Limited use in certain cases such as women with ruptured membranes, placental abnormalities, or certain medical conditions
  • 5.3 Intrauterine Pressure Catheters Market Opportunities
    • 5.3.1 Undergoing improvements in catheter technology are making intrauterine pressure catheters safer and applicable to more routine cases

6. Intrauterine Pressure Catheters Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Intrauterine Pressure Catheters Market Assessment

  • 7.1 By Product
    • 7.1.1 Fluid-Filled Catheters
    • 7.1.2 Transducer Tip Catheters
  • 7.2 By End-User
    • 7.2.1 Hospitals
    • 7.2.2 Ambulatory Surgical Centers (ASCs)
    • 7.2.3 Specialty Clinics
  • 7.3 By Geography
    • 7.3.1 North America
      • 7.3.1.1 United States Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.1.2 Canada Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.1.3 Mexico Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
    • 7.3.2 Europe
      • 7.3.2.1 France Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.2.2 Germany Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.2.3 United Kingdom Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.2.4 Italy Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.2.5 Spain Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.2.6 Rest of Europe Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
    • 7.3.3 Asia-Pacific
      • 7.3.3.1 China Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.3.2 Japan Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.3.3 India Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.3.4 Australia Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.3.5 South Korea Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.3.6 Rest of Asia-Pacific Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
    • 7.3.4 Rest of the World (RoW)
      • 7.3.4.1 Middle East Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.4.2 Africa Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)
      • 7.3.4.3 South America Intrauterine Pressure Catheters Market Size in USD Million (2022-2032)

8. Intrauterine Pressure Catheters Market Company and Product Profiles

  • 8.1 Cardinal Health
    • 8.1.1 Company Overview
    • 8.1.2 Company Snapshot
    • 8.1.3 Financial Overview
    • 8.1.4 Product Listing
    • 8.1.5 Entropy
  • 8.2 Koninklijke Philips N.V.
    • 8.2.1 Company Overview
    • 8.2.2 Company Snapshot
    • 8.2.3 Financial Overview
    • 8.2.4 Product Listing
    • 8.2.5 Entropy
  • 8.3 Utah Medical Products, Inc.
    • 8.3.1 Company Overview
    • 8.3.2 Company Snapshot
    • 8.3.3 Financial Overview
    • 8.3.4 Product Listing
    • 8.3.5 Entropy
  • 8.4 CooperSurgical Inc.
    • 8.4.1 Company Overview
    • 8.4.2 Company Snapshot
    • 8.4.3 Financial Overview
    • 8.4.4 Product Listing
    • 8.4.5 Entropy
  • 8.5 Thomas Medical
    • 8.5.1 Company Overview
    • 8.5.2 Company Snapshot
    • 8.5.3 Financial Overview
    • 8.5.4 Product Listing
    • 8.5.5 Entropy
  • 8.6 VYAIRE
    • 8.6.1 Company Overview
    • 8.6.2 Company Snapshot
    • 8.6.3 Financial Overview
    • 8.6.4 Product Listing
    • 8.6.5 Entropy
  • 8.7 Laborie
    • 8.7.1 Company Overview
    • 8.7.2 Company Snapshot
    • 8.7.3 Financial Overview
    • 8.7.4 Product Listing
    • 8.7.5 Entropy
  • 8.8 LABOTECT GMBH
    • 8.8.1 Company Overview
    • 8.8.2 Company Snapshot
    • 8.8.3 Financial Overview
    • 8.8.4 Product Listing
    • 8.8.5 Entropy
  • 8.9 Kentec Medical, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Company Snapshot
    • 8.9.3 Financial Overview
    • 8.9.4 Product Listing
    • 8.9.5 Entropy
  • 8.10. General Electric Company
    • 8.10.1 Company Overview
    • 8.10.2 Company Snapshot
    • 8.10.3 Financial Overview
    • 8.10.4 Product Listing
    • 8.10.5 Entropy
  • 8.11. Femasys Inc.
    • 8.11.1 Company Overview
    • 8.11.2 Company Snapshot
    • 8.11.3 Financial Overview
    • 8.11.4 Product Listing
    • 8.11.5 Entropy
  • 8.12. MicroPort Scientific Corporation
    • 8.12.1 Company Overview
    • 8.12.2 Company Snapshot
    • 8.12.3 Financial Overview
    • 8.12.4 Product Listing
    • 8.12.5 Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦